MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

Search

Stryker Corp

Gesloten

SectorGezondheidszorg

338.74 -0.31

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

333.42

Max

340.02

Belangrijke statistieken

By Trading Economics

Inkomsten

-10M

849M

Verkoop

1.1B

7.2B

K/W

Sectorgemiddelde

39.607

66.418

EPS

4.47

Dividendrendement

1.03

Winstmarge

11.839

Werknemers

56,000

EBITDA

351M

1.7B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+25.49% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.03%

2.36%

Volgende Winsten

30 apr 2026

Volgende dividenddatum

30 apr 2026

Volgende Ex Dividend datum

29 jun 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-9.3B

127B

Vorige openingsprijs

339.05

Vorige sluitingsprijs

338.74

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Stryker Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 mrt 2026, 21:42 UTC

Belangrijke Nieuwsgebeurtenissen

Stryker Says Cyberattack Disruption Is Continuing

11 mrt 2026, 19:18 UTC

Belangrijke Marktbewegers

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

29 jan 2026, 22:05 UTC

Winsten

Stryker Logs Higher 4Q Profit On Sales Gains

30 okt 2025, 20:36 UTC

Winsten

Stryker Lifts Fiscal Year Sales View After 3Q Revenue Rises

31 jul 2025, 20:42 UTC

Winsten

Stryker Lifts Guidance on Improving Tariff Outlook

9 apr 2026, 20:55 UTC

Winsten

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9 apr 2026, 20:55 UTC

Winsten

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9 apr 2026, 20:55 UTC

Winsten

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

16 mrt 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

Hack on U.S. Medical Company Shows Reach of Iran's Cyber Capabilities -- WSJ

30 jan 2026, 17:03 UTC

Marktinformatie

Stryker's 4Q Results Signal 2026 Growth -- Market Talk

29 jan 2026, 21:07 UTC

Winsten

Stryker Sees 2026 Organic Net Sales Growth 8%-9.5%

29 jan 2026, 21:05 UTC

Winsten

Stryker 4Q Adj EPS $4.47 >SYK

5 nov 2025, 19:38 UTC

Winsten

This Healthcare Stock Is the Worst Performer in the S&P 500 Today. Here's Why. -- Barrons.com

5 nov 2025, 17:00 UTC

Winsten

This Healthcare Stock Is Worst Performer in the S&P 500 Today. Here's Why. -- Barrons.com

30 okt 2025, 20:21 UTC

Winsten

Stryker Lifts FY Sales View After 3Q Revenue Rises

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Adj EPS $3.19 >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q EPS $2.22 >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Sales $6.1B >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Net $859M >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker Sees FY Adj EPS $13.50-Adj EPS $13.60 >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Adj EPS $3.19 >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Net $859M >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q Sales $6.06B >SYK

30 okt 2025, 20:05 UTC

Winsten

Stryker 3Q EPS $2.22 >SYK

31 jul 2025, 20:09 UTC

Winsten

Stryker Estimates Net Impact From Tariffs in 2025 of Approximately $175M

31 jul 2025, 20:09 UTC

Winsten

Stryker Sales >SYK

31 jul 2025, 20:09 UTC

Winsten

Stryker Sees FY25 Organic Net Sales Up 9.5%-10%

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q Sales $6B >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker 2Q Net $884M >SYK

31 jul 2025, 20:05 UTC

Winsten

Stryker Sees FY Adj EPS $13.40-Adj EPS $13.60 >SYK

Peer Vergelijking

Prijswijziging

Stryker Corp Prognose

Koersdoel

By TipRanks

25.49% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 426.68 USD  25.49%

Hoogste 469 USD

Laagste 357 USD

Gebaseerd op 21 Wall Street-analisten die 12-maands prijsdoelen bieden voor Stryker Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

21 ratings

17

Buy

4

Hold

0

Sell

Technische score

By Trading Central

373.92 / 383.99Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Stryker Corp

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
help-icon Live chat